Aura Biosciences price target lowered to $19 from $21 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Aura Biosciences (AURA) to $19 from $21 and keeps an Outperform rating on the shares. Aura’s Phase 1 data in bladder cancer are “promising,” supporting bel-sar’s proof of concept by highlighting the early responses, clean safety, and ease of administration which will all be key differentiators, the analyst tells investors in a research note. The new $19 price target is supported by bel-sar’s opportunity in uveal melanoma alone with bladder cancer, choroidal metastasis, and ocular surface cancer representing upside, Citizens says.